HOUSE 1143119th CongressReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Medicare IVIG Access Enhancement Act of 2025
- Last Action
- 2/7/2025
Actions
- 2025-02-07Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-07Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-07Introduced in House
- 2025-02-07Introduced in House
CRS Summary
As of 2025-02-07 (00)
Medicare IVIG Access Enhancement Act of 2025
This bill provides for Medicare coverage of in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy. (CIDP is an autoimmune condition that causes symptoms such as muscle weakness and numbness; multifocal motor neuropathy is a variant of CIDP that only causes asymmetric muscle weakness.)
Cosponsors (2)
- John Garamendi (D-CA)
- Eugene Vindman (D-VA)
Subjects
- Drug therapy
- Health care costs and insurance
- Health care coverage and access
- Medicare
- Neurological disorders
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.